Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 12/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768808 | 0.79 | CYP2D6 (0.41) | CYP2D6CXCR4HDAC1HDAC6IDO1 | |
| SCHEMBL2877878 | 0.79 | OPRL1 (0.39) | — | |
| SCHEMBL2883261 | 0.79 | OPRL1 (0.39) | — | |
| SCHEMBL16237845 | 0.78 | — | — | |
| SCHEMBL16237130 | 0.78 | — | — | |
| SCHEMBL16237132 | 0.78 | — | — | |
| SCHEMBL2880299 | 0.78 | OPRL1 (0.35) | — | |
| SCHEMBL12975879 | 0.78 | OPRL1 (0.37) | — | |
| SCHEMBL29127921 | 0.76 | NISCH (0.31) | — | |
| SCHEMBL29127929 | 0.76 | NISCH (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | CYP2D6 1197/4885CXCR4 2044/4885CYP3A4 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.